Supernus Pharmaceuticals, Inc. Form 8-K Filing

This Form 8-K filing by Supernus Pharmaceuticals, Inc. reports on the entry into an Asset Purchase Agreement with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC. The agreement, effective April 1, 2026, involves the acquisition of assets related to the compound known as NV-5138 or SPN-820. These assets include intellectual property rights, inventory, manufacturing materials, regulatory and clinical materials, permits, data, records, and related goodwill. The purchase price is contingent upon the completion of a Phase 2b Study and potential milestone payments totaling up to $350 million, based on specified development, regulatory, and commercial achievements. The agreement includes customary representations, warranties, and indemnification provisions. Supernus Pharmaceuticals has agreed to use commercially reasonable efforts to achieve milestones, but has the discretion to cease further obligations if the Phase 2b Study is deemed unsuccessful. The filing also incorporates by reference the Asset Purchase Agreement as an exhibit.